Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure.

Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Abstract Text:

Eric E Morgan,Martin E Young,Tracy A McElfresh,Theodore A Kung,Brian D Hoit,Margaret P Chandler,William C Stanley,

Trimetazidine (TMZ) is effective for the treatment of ischemic cardiomyopathy; however, little is known about the effect of TMZ in established injury-induced heart failure. When rats with established infarct-induced heart failure were treated for 12 weeks with TMZ there was no effect on left ventricular function or dilation, or on mRNA expression of fatty acid oxidation enzymes. On the other hand, TMZ significantly reduced atrial natriuretic peptide mRNA levels compared with untreated rats.

Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Publishing Authors By Initials

EE Morgan,ME Young,TA McElfresh,TA Kung,BD Hoit,MP Chandler,WC Stanley,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Fundamental & clinical pharmacology

VOLUME: 20

Page Numbers: 503-5

Journal Abbreviation:

ISSN: 0767-3981

DAY: 3

MONTH: Oct

YEAR: 2006

Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8710411

Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure.

AFFILIATION: Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Fundam Clin Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure Related Publications

• A web-based breastfeeding education program.
• Borderline personality disorder, stigma, and treatment implications.
• Cardiac energy metabolism in obesity.
• Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high-fat diet.
• Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure.
• Computer simulations of Alzheimer's amyloid beta-protein folding and assembly.
• Deleterious effects of sugar and protective effects of starch on cardiac remodeling, contractile dysfunction, and mortality in response to pressure overload.
• Diabetes or peroxisome proliferator-activated receptor alpha agonist increases mitochondrial thioesterase I activity in heart.
• Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
• Dynamic encoding of natural luminance sequences by LGN bursts.
• Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach.
• Fertilization in mouse does not require terminal galactose or N-acetylglucosamine on the zona pellucida glycans.
• High fructose diet increases mortality in hypertensive rats compared to a complex carbohydrate or high fat diet.
• Lectin-resistant CHO glycosylation mutants.
• Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension.
• Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates.
• Numerical evaluation of the upper critical dimension of percolation in scale-free networks.
• Parallel activation of mitochondrial oxidative metabolism with increased cardiac energy expenditure is not dependent on fatty acid oxidation in pigs.
• Pombe Cdc15 homology (PCH) proteins: coordinators of membrane-cytoskeletal interactions.
• Relation between the Widom line and the breakdown of the Stokes-Einstein relation in supercooled water.
• Resistance of presynaptic CaV2.2 channels to voltage-dependent inactivation: dynamic palmitoylation and voltage sensitivity.
• Role of cellular compartmentation in the metabolic response to stress: mechanistic insights from computational models.
• Role of electrostatic interactions in amyloid beta-protein (A beta) oligomer formation: a discrete molecular dynamics study.
• Roles of O-fucose glycans in notch signaling revealed by mutant mice.
• Signal detection of salient visual features by the early visual pathway.
• Targeting pemphigus autoantibodies through their heavy-chain variable region genes.
• The threonine that carries fucose, but not fucose, is required for Cripto to facilitate Nodal signaling.
• Transcriptomic comparison of two Entamoeba histolytica strains with defined virulence phenotypes identifies new virulence factor candidates and key differences in the expression patterns of cysteine proteases, lectin light chains, and calmodulin.
• Transgenic expression of CSF-1 in CSF-1 receptor-expressing cells leads to macrophage activation, osteoporosis, and early death.
• Vaccines for amoebiasis: barriers and opportunities.